Patrick Daly

DocwireNews

In a meta-analysis published in&nbsp;Frontiers in Immunology, researchers evaluated the safety and efficacy of Janus kinase (JAK) inhibitors with or without <a href="https://medlineplus.gov/druginfo/meds/a682019.html">methotrexate</a> in patients with active rheumatoid arthritis. According to the study&rsquo;s authors, JAK inhibitors in combination with methotrexate were superior to JAK inhibitor monotherapy based on American College of Rheumatology (ACR) criteria, disease activity, and remission incidence.The meta-analysis included three randomized controlled trials encompassing 2290 patients that were published to the Medline, Embase, and Cochrane Library databases. The researchers conducted pooled analysis used random-effects models and identified risk differences (RD) between the two groups. The JAK inhibitors in the enrolled studies included tofacitinib, baricitinib, and filgotinib.<h3>JAK Inhibitor and Methotrexate Superior to JAK Inhibitor Monotherapy</h3>According to the report, patients in the JAK inhibitor plus methotrexate group had a higher proportion of patients who met the ACR criteria compared with the JAK inhibitor monotherapy group at week 52:<ul>
<li>ACR20: RD, 0.032; 95% CI, -0.027 to 0.091</li>
<li>ACR50: RD, 0.050; 95% CI, 0.003-0.097</li>
<li>ACR70: RD, 0.056; 95% CI, 0.012-0.100</li>
</ul>Additionally, the authors reported that the differences in ACR20, ACR50, and ACR70&nbsp; between the two groups were also similar at week 24. Furthermore, the groups had no significant differences in the proportion of patients who improved by 0.22 or more on the Health Assessment Questionnaire disability index (HAQ-DI) at weeks 24 and 52.Comparatively, the authors found that JAK inhibitors plus methotrexate exhibited higher response rates and lower disease activity compared with JAK inhibitor monotherapy at 24 and 52 weeks. Notably, the combination regimen showed a higher risk of treatment-emergent adverse events and adverse events leading to treatment discontinuation.Overall, the researchers summarized that JAK inhibitor <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/impact-of-methotrexate-withdrawal-on-successfully-treated-rheumatoid-arthritis/">plus methotrexate</a> regimens appeared superior to JAK inhibitor monotherapy based on ACR response, disease activity, and remission. &ldquo;The two regimens presented comparable physical functioning measured by HAQ-DI improvement and similar tolerability, except for high risks of TEAEs and AEs leading to study discontinuation in combination therapy,&rdquo; they closed.View More <a href="https://www.docwirenews.com/rheumatoid-arthritis-resource-center/">Rheumatoid Arthritis Research on the DocWire News Resource Center</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

JAK Inhibitors With or Without Methotrexate in Rheumatoid Arthritis

Rheumatoid Arthritis

In a meta-analysis published in Frontiers in Immunology, researchers evaluated the safety and efficacy of Janus kinase (JAK) inhibitors with or without methotrexate in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe